BC Week In Review | Oct 3, 2016
Clinical News

Faldaprevir: Interim Phase IIa data

Interim data from 11 treatment-naive, non-cirrhotic patients with chronic HCV genotype 4 infection in an open-label, U.S. Phase IIa trial showed that once-daily 60 and 120 mg TD-6450 plus once-daily 120 mg oral faldaprevir and...
BC Week In Review | Oct 3, 2016
Clinical News

TD-6450: Interim Phase IIa data

Interim data from 11 treatment-naive, non-cirrhotic patients with chronic HCV genotype 4 infection in an open-label, U.S. Phase IIa trial showed that once-daily 60 and 120 mg TD-6450 plus once-daily 120 mg oral faldaprevir and...
BC Week In Review | Jul 18, 2016
Clinical News

Faldaprevir: Phase IIa started

Trek began an open-label, international Phase IIa trial to evaluate once-daily 120 mg oral TD-6450 plus 120 mg oral faldaprevir with and without ribavirin for 12 weeks in 25 patients. Trek has exclusive, worldwide rights...
BC Week In Review | Jul 18, 2016
Clinical News

TD-6450: Phase IIa started

Trek began an open-label, international Phase IIa trial to evaluate once-daily 120 mg oral TD-6450 plus 120 mg oral faldaprevir ( BI 201335 ) with and without ribavirin for 12 weeks in 25 patients. Trek has exclusive,...
BC Week In Review | Nov 23, 2015
Clinical News

Faldaprevir: Phase IIa started

Trek began a double-blind, U.S. Phase IIa trial to evaluate 60 and 120 mg TD-6450 once daily with 120 mg oral faldaprevir once daily and ribavirin twice daily for 12 weeks in about 24 treatment-naive...
BC Week In Review | Nov 23, 2015
Clinical News

TD-6450: Phase IIa started

Trek began a double-blind, U.S. Phase IIa trial to evaluate 60 and 120 mg TD-6450 once daily with 120 mg oral faldaprevir once daily and ribavirin twice daily for 12 weeks in about 24 treatment-naive...
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
BC Week In Review | Jun 30, 2014
Clinical News

Faldaprevir regulatory update

Boehringer Ingelheim said it is exiting the HCV space because it does not have an angle on an interferon-free regimen. The company said it will withdraw all pending marketing applications for faldaprevir that cover use...
BC Extra | Jun 24, 2014
Company News

Boehringer exiting HCV

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it is exiting the HCV space because it does not have an angle on an interferon-free regimen. The company said it will withdraw all pending marketing applications for faldaprevir,...
BioCentury | Mar 24, 2014
Strategy

The price of success

Payers are so far covering the new HCV drugs from Gilead Sciences Inc. and Johnson & Johnson , but they are already looking forward to new drugs expected to hit the market in the next 18...
Items per page:
1 - 10 of 67